We then discuss several potential strategies for combating tauopathies in the context of phase separation: (i) modulating the formation of tau condensates, (ii) delaying the liquid-to-solid transition of tau condensates, (iii) reducing the enrichment of aggregation-prone species into tau condensates, and (iv) suppressing abnormal post-translational modifications on tau inside condensates. The gene discussed is MAPT; the disease is tauopathy.